#1 Clinical Trials Search in Europe

Eteplirsen

Eteplirsen is an investigational drug being studied in clinical trials for the treatment of Duchenne muscular dystrophy (DMD). DMD is a rare genetic disorder characterized by progressive muscle degeneration and weakness. Eteplirsen aims to increase production of dystrophin, a key protein lacking in DMD patients. This article summarizes key information about clinical trials evaluating the safety and efficacy of eteplirsen in DMD patients.

Table of Contents

What is Eteplirsen?

Eteplirsen, also known by its brand names EXONDYS 51, EXONDYS, or AVI-4658, is a medication designed to treat Duchenne Muscular Dystrophy (DMD)[1][2]. DMD is a rare, serious, and progressive genetic disorder that primarily affects boys, causing muscle weakness and eventual loss of mobility[3].

Eteplirsen is specifically developed for DMD patients with genetic mutations that are amenable to exon 51 skipping. This means it’s not suitable for all DMD patients, but only those with specific genetic characteristics[4].

How Eteplirsen Works

Eteplirsen works through a mechanism called exon skipping. In DMD, there’s a problem with the production of a protein called dystrophin, which is crucial for muscle strength and function. Eteplirsen is designed to “skip” over a faulty part of the genetic code (specifically exon 51), allowing the body to produce a shortened but partially functional dystrophin protein[5].

By increasing the amount of dystrophin in muscle cells, the goal is to slow down the progression of the disease and potentially improve muscle function[6].

How Eteplirsen is Administered

Eteplirsen is given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. Typically, patients receive weekly infusions. The dose is usually based on the patient’s weight, with common doses being 30 mg/kg or 50 mg/kg[7][8].

The infusion process usually takes about 60 minutes and is performed in a healthcare setting under medical supervision[9].

Efficacy of Eteplirsen

Research on eteplirsen has focused on several key areas to measure its effectiveness:

  • Dystrophin Production: Studies have shown that eteplirsen can increase the production of dystrophin in muscle cells[8].
  • Walking Ability: The 6-Minute Walk Test (6MWT) is often used to assess how far patients can walk in 6 minutes. Some studies have shown that eteplirsen may help maintain or slow the decline in walking ability[9].
  • Lung Function: Researchers also monitor changes in lung function, as respiratory decline is a serious complication of DMD[3].

It’s important to note that while some patients have shown benefits, the effectiveness can vary among individuals[6].

Safety and Side Effects

Clinical trials have generally found eteplirsen to be well-tolerated, but like all medications, it can have side effects. Common side effects may include:

  • Balance disorders
  • Vomiting
  • Contact dermatitis (skin reaction)

More serious side effects are rare but can include hypersensitivity reactions. Doctors closely monitor patients for any adverse reactions, particularly during and immediately after infusions[1][2].

Ongoing Research

Eteplirsen continues to be studied in various clinical trials. Researchers are looking at its long-term effects, optimal dosing, and potential benefits in different age groups of DMD patients. Some studies are also exploring higher doses of eteplirsen to see if they might provide additional benefits[6].

Additionally, there’s ongoing research into similar drugs for DMD patients with different genetic mutations, such as golodirsen (VYONDYS 53) for exon 53 skipping and casimersen (AMONDYS 45) for exon 45 skipping[10].

Important Considerations for Patients

If you or your child has DMD, here are some important points to consider about eteplirsen:

  • Genetic Testing: Eteplirsen is only suitable for DMD patients with mutations amenable to exon 51 skipping. Genetic testing is necessary to determine if you’re eligible for this treatment[4].
  • Long-Term Treatment: Eteplirsen is not a cure for DMD, but a treatment aimed at slowing disease progression. It typically requires ongoing, weekly treatments[7].
  • Monitoring: Regular check-ups and tests are necessary to monitor the effectiveness of the treatment and watch for any side effects[2].
  • Combination with Other Therapies: Eteplirsen is often used alongside other treatments for DMD, such as corticosteroids and physical therapy[10].

Always consult with your healthcare provider for personalized advice about treatment options for DMD. They can provide the most up-to-date information and help determine if eteplirsen is appropriate for your specific situation.

Aspect Details
Drug Name Eteplirsen (also known as AVI-4658, EXONDYS 51)
Target Condition Duchenne Muscular Dystrophy (DMD)
Mechanism of Action Exon 51 skipping to increase dystrophin production
Administration Intravenous (IV) infusion, typically weekly
Common Doses 30 mg/kg, 50 mg/kg, with some trials exploring higher doses (100 mg/kg, 200 mg/kg)
Primary Outcomes Changes in dystrophin levels, 6-minute walk test performance, safety assessments
Secondary Outcomes Other functional tests, muscle strength, respiratory function, quality of life measures
Trial Durations Typically 48-96 weeks, with some extending to 144 weeks or longer
Patient Populations DMD patients with mutations amenable to exon 51 skipping, various age ranges studied
Safety Monitoring Adverse events, laboratory tests, ECGs, echocardiograms, physical examinations

FAQ

  • What is eteplirsen? Eteplirsen is an investigational drug designed to treat Duchenne muscular dystrophy (DMD). It works by helping the body produce dystrophin, an important protein that is missing or defective in people with DMD.
  • How is eteplirsen administered? Eteplirsen is given as an intravenous (IV) infusion, typically once a week. The dose and duration vary between trials, but common doses are 30 mg/kg or 50 mg/kg given weekly.
  • What are the main goals of the eteplirsen clinical trials? The main goals are to evaluate the safety, tolerability, and effectiveness of eteplirsen in DMD patients. Trials aim to assess if eteplirsen can increase dystrophin production and improve or slow the decline of muscle function.
  • What are some of the key outcomes measured in these trials? Key outcomes include changes in dystrophin levels in muscle biopsies, performance on the 6-minute walk test, other functional tests like rising from the floor, and safety assessments including adverse events and laboratory tests.
  • How long do the eteplirsen clinical trials typically last? The duration varies, but many trials last 48-96 weeks or longer. Some have extension phases allowing participants to continue treatment for additional years to assess long-term effects.

Ongoing Clinical Trials on Eteplirsen

  • Study on Eteplirsen for Patients with Duchenne Muscular Dystrophy with Deletion Mutations Amenable to Exon 51 Skipping

    Not recruiting

    3 1 1
    Investigated drugs:
    Czechia Denmark France Germany Greece Hungary +7

Glossary

  • Duchenne muscular dystrophy (DMD): A genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact.
  • Eteplirsen: An investigational drug designed to treat DMD by helping the body produce dystrophin. Also known as AVI-4658 or EXONDYS 51.
  • Exon skipping: A therapeutic approach aimed at 'skipping' over faulty parts of genes to allow the production of partially functional proteins.
  • Dystrophin: A protein that helps keep muscle cells intact. It is absent or defective in people with DMD.
  • 6-minute walk test (6MWT): A clinical test measuring the distance an individual can walk in 6 minutes to assess functional capacity.
  • Immunohistochemistry (IHC): A method for detecting specific proteins in tissues, used to measure dystrophin levels in muscle biopsies.
  • Western blot: A laboratory technique used to detect specific proteins in a sample of tissue, used to quantify dystrophin levels.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Open-label study: A type of clinical trial in which both the researchers and participants know which treatment is being administered.

References

  1. https://clinicaltrials.gov/study/NCT03985878
  2. https://clinicaltrials.gov/study/NCT02286947
  3. https://clinicaltrials.gov/study/NCT02255552
  4. https://clinicaltrials.gov/study/NCT03218995
  5. https://clinicaltrials.gov/study/NCT04179409
  6. https://clinicaltrials.eu/trial/study-on-eteplirsen-for-patients-with-duchenne-muscular-dystrophy-with-deletion-mutations-amenable-to-exon-51-skipping/
  7. https://clinicaltrials.gov/study/NCT02420379
  8. https://clinicaltrials.gov/study/NCT01540409
  9. https://clinicaltrials.gov/study/NCT01396239
  10. https://clinicaltrials.gov/study/NCT06606340